SynSmart Rasayan Research and Amporin Pharmaceuticals AG have collaborated to develop breakthrough small molecule therapeutics for the treatment of deadly degenerative diseases.

Under the terms of this collaboration, SynSmart will synthesise a substantial library of novel membrane-protecting molecules at its Mumbai research facility.

Commenting on this, Saurabh Kapure, CEO, SynSmart, said, “This collaboration is a testimony of value that SynSmart can bring to the table for its partners. With lab operations running in multi-shift mode and lean team hierarchy, the speed and cost-savings help partners get more done for less.”

Upon screening, the collaboration could be extended to follow-on chemistry as well as potential work in ADME-PK areas, with the intention to accelerate the project to candidate selection.

Also commenting on this, Dr. Kelvin Stott, Founder and CEO, Amporin, said, “We are excited to form this collaboration with SynSmart as it will accelerate the cross-target screening, optimisation and selection of disease-modifying treatments for multiple deadly degenerative diseases in parallel, while validating the scope and potential of our unique asset platform.”